Table 1 Comparison of exercise and control group at baseline
| Â | Total (n = 37) | Exercise group (n = 24) | Control group (n = 13) | P |
|---|---|---|---|---|
Demographic | ||||
 Age, years | 49.9 ± 7.9 | 51.2 ± 6.9 | 47.6 ± 9.3 | 0.258 |
Anthropometric | ||||
 Height, cm | 158.4 ± 4.9 | 157.5 ± 4.6 | 159.9 ± 5.3 | 0.122 |
 Weight, kg | 61.4 ± 10.5 | 61.4 ± 8.8 | 61.5 ± 13.5 | 0.310 |
 Body mass index, kg/m2 | 24.4 ± 3.8 | 24.7 ± 3.7 | 23.9 ± 4.3 | 0.417 |
RA-related characteristics | ||||
 Disease duration, years | 5.9 ± 7.4 | 6.7 ± 7.5 | 4.4 ± 7.4 | 0.070 |
 Rheumatoid factor positivity | 28 (75.7) | 19 (79.2) | 9 (69.2) | 0.423 |
 Anti-CCP antibody positivity | 30 (81.1) | 21 (87.5) | 9 (69.2) | 0.423 |
 ESR, mm/h | 20.7 ± 15.2 | 22.5 ± 14.4 | 17.3 ± 16.7 | 0.325 |
 CRP, mg/dl | 0.3 ± 0.7 | 0.4 ± 0.8 | 0.1 ± 0.1 | 0.226 |
 DAS28-ESR | 3.0 ± 1.0 | 3.2 ± 0.8 | 2.6 ± 1.2 | 0.070 |
 DAS28-CRP | 2.4 ± 0.8 | 2.5 ± 0.7 | 2.1 ± 0.9 | 0.047 |
 RA medication |  |  |  | 0.413 |
 cDMARD monotherapy | 10 (27.0) | 7 (29.2) | 3 (23.1) |  |
 cDMARD combination | 21 (56.8) | 12 (50.0) | 9 (69.2) |  |
 Biologics | 6 (16.2) | 5 (20.8) | 1 (7.7) |  |
Body composition | ||||
 Fat mass, kg | 22.5 ± 7.6 | 22.9 ± 7.4 | 21.8 ± 8.1 | 0.683 |
 Fat free mass, kg | 39.2 ± 4.5 | 38.3 ± 3.4 | 40.8 ± 5.8 | 0.115 |
 Visceral fat area, cm2 | 113.3 ± 44.2 | 117.2 ± 43.5 | 106.3 ± 46.2 | 0.482 |